Monoclonal antibody (mAb) recognizes a unique part of the antigen specifically, e.g. tumor associated antigens like EGFR or HER-2, and these mAbs have been widely used as standard treatment in clinical trails. This evidence concerns the gene ERBB2 and neoplasm.